Weiss Ratings Reiterates Sell (D-) Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)

Phathom Pharmaceuticals (NASDAQ:PHAT)‘s stock had its “sell (d-)” rating reissued by analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen raised Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 18th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Phathom Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $17.50.

Phathom Pharmaceuticals Price Performance

NASDAQ:PHAT opened at $13.53 on Friday. Phathom Pharmaceuticals has a fifty-two week low of $2.21 and a fifty-two week high of $19.50. The stock’s 50-day moving average is $12.04 and its two-hundred day moving average is $8.64. The stock has a market cap of $959.82 million, a PE ratio of -2.86 and a beta of 0.43.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Phathom Pharmaceuticals during the 1st quarter valued at about $3,738,000. Russell Investments Group Ltd. acquired a new stake in shares of Phathom Pharmaceuticals during the 1st quarter valued at about $262,000. US Bancorp DE lifted its holdings in shares of Phathom Pharmaceuticals by 248.1% during the 1st quarter. US Bancorp DE now owns 23,763 shares of the company’s stock valued at $149,000 after buying an additional 16,937 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Phathom Pharmaceuticals by 47.6% during the 1st quarter. Wellington Management Group LLP now owns 200,690 shares of the company’s stock valued at $1,258,000 after buying an additional 64,695 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Phathom Pharmaceuticals in the 1st quarter worth approximately $565,000. 99.01% of the stock is currently owned by institutional investors and hedge funds.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.